Why Zymeworks Inc.’s (ZYME) Stock Is Up 5.07%
As of Thursday, September 17, Zymeworks Inc.’s ZYME share price has surged by 5.07%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Commentary & Analysis
Which Is a Better Investment, CareDx, Inc. or Zymeworks Inc. Stock?
Learn more about whether CareDx, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Which Is a Better Investment, Nurix Therapeutics, Inc. or Zymeworks Inc. Stock?
Learn more about whether Nurix Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, uniQure N.V. or Zymeworks Inc. Stock?
Learn more about whether uniQure N.V. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Vericel Corporation or Zymeworks Inc. Stock?
Learn more about whether Vericel Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Financial Summary
| Share Statistics | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,902.4 | $269.5 | 53% |
|
| Shares Out (Mil) | 73.0 | 54.2 | 56% |
|
| Institutional Ownership | 97.2% | 93.0% | 73% |
|
| Float (Mil) | 65.8 | 42.1 | 53% |
|
| Beta | 1.15 | 0.95 | 68% |
|
| Avg Daily Volume (000s) | 734 | 609 | 63% |
|
| Price Change (52-week) |
62.6% | 54.5% | 87% |
|
| Growth | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.1% | 13.6% | 83% |
|
| Net Income (5yr) | 14.8% | (10.1%) | 63% |
|
| EPS (5yr) | 21.4% | 15.4% | 71 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | $2.288 | $1.105 | $0.922 | |
| Month Ago EPS | $1.612 | $1.122 | $1.177 | |
| # Rev Up | 1 | 1 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $1.658 | $1.264 | $0.683 | |
| Year/Year Chg | (469.0%) | (202.5%) | (121.4%) | |
| Financials | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $37 | 18% |
|
| Net Income (TTM) (Mil) | ($150) | ($43) | 9% |
|
| EPS (TTM) | ($2.008) | ($1.500) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($119) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $81 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $1,728 | $175 | 47% |
|
| Valuation | ZYME | Industry Median |
Percentile (All Stocks) |
|
| P/B | 23.73 | 2.60 | 96% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (246.7%) | 68.9% | 1% |
|
| Net Margin | (404.0%) | (72.5%) | 2% |
|
| ROA | (37.2%) | (47.4%) | 14% |
|
| ROE | (72.3%) | (54.9%) | 12% |
|
| Liabilities to Assets | 79.8% | 29.3% | 75% |
|
| F-Score | 2 | 3 | 7% |
|
Zymeworks Inc. did not pass any screens on 9/21/2026.
